The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma.

  • Carmelo Caldarella Institute of Nuclear Medicine, PET/CT Center, Catholic University, Rome, Italy
  • Barbara Muoio School of Medicine, Catholic University, Rome, Italy
  • Maria Antonietta Isgro' Institute of Biochemistry and Clinical Biochemistry, Catholic University, Rome, Italy
  • Emilio Porfiri
  • Giorgio Treglia Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
  • Luca Giovanella Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Abstract

Purpose: Positron emission tomography-computed tomography (PET-CT) using fluorodeoxyglucose (FDG) is increasingly used in the evaluation of patients with advanced renal cell carcinoma (RCC), primarily for staging purposes. The aim of this paper is to perform a systematic review about the usefulness of PET-CT using FDG in response assessment after treatment with tyrosine-kinase inhibitors (TKIs) in patients with advanced RCC.

Methods: The scientific literature about the role of PET-CT using FDG in the assessment of response to treatment with TKIs in patients affected by advanced RCC was systematically reviewed.

Results: Seven studies about the role of PET-CT using FDG in the response assessment after treatment with TKIs (essentially sunitinib and sorafenib) in advanced RCC were retrieved in full-text and analyzed, to determine the predictive role of this morpho-functional imaging method on patient’s outcome.

Conclusions: to date, the role of PET-CT using FDG in evaluating the response to TKIs in metastatic RCC patients is still not well defined, partly due to heterogeneity of available studies; however, PET-CT reveals a potential role for the selection of patients undergoing therapy with TKIs. Use of contrast-enhanced PET-CT appears to be promising for a “multi-dimensional” evaluation of treatment response in these patients.

Published
2014-08-27
How to Cite
Caldarella, C., Muoio, B., Isgro’, M. A., Porfiri, E., Treglia, G., & Giovanella, L. (2014). The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma. Radiology and Oncology, 48(3). Retrieved from https://radioloncol.com/index.php/ro/article/view/1550
Section
Review